Urolithin Composition for Muscle Mass Preservation and Kidney Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Muscle decline and kidney dysfunction associated with chronic kidney disease (CKD) lead to significant morbidity and mortality, with existing treatments failing to effectively address muscle wasting and kidney function deterioration.
Innovation Solution
Administration of a composition comprising urolithin or its pharmaceutically acceptable salt, which is effective in treating and preventing muscle decline and kidney dysfunction, improving lean muscle mass, increasing urinary creatinine, decreasing the albumin/creatinine ratio, and enhancing albumin reabsorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for chronic kidney disease, then kidney function is managed, but muscle wasting and muscle mass loss occur
Solution Approach 1:
The patent introduces urolithin A as an intermediary compound that mediates between kidney function management and muscle mass preservation. Urolithin A acts through the NAD+ pathway, serving as a bridge that simultaneously addresses renal function while preventing catabolic muscle wasting through activation of SIRT1 and PGC-1α, thereby resolving the contradiction between managing kidney disease and preserving muscle mass
2Reliability
If catabolic pathways are activated in CKD, then kidney disease progression is addressed, but muscle regeneration is impaired
Solution Approach 1:
The patent applies preliminary anti-action by using urolithin A to preemptively counteract the harmful effects of catabolic pathway activation. Before severe muscle wasting occurs, urolithin A activates anabolic pathways through NAD+ enhancement, SIRT1 activation, and PGC-1α upregulation, creating a protective effect that prevents muscle regeneration impairment while allowing controlled management of kidney disease progression
3Productivity
If protein degradation increases in muscle wasting, then metabolic turnover is enhanced, but muscle mass decreases
Solution Approach 1:
The patent employs parameter changes by modulating the balance between protein degradation and synthesis through urolithin A administration. By enhancing NAD+ levels and activating SIRT1/PGC-1α pathways, the invention shifts the metabolic parameters toward reduced catabolism and enhanced anabolism, thereby maintaining muscle mass while preserving necessary metabolic turnover for kidney disease management
Data Source
AI summary
The present disclosure generally relates to methods and compositions comprising urolithin that treat or prevent a disease or condition associated with muscle decline and/or a kidney dysfunction. Moreover, methods and compositions comprising urolithin for increasing the urinary creatinine and/or for decreasing the albumin/creatinine ratio and/or for increasing the albumin reabsorption. In addition, methods and compositions comprising urolithin to improve the lean mass of a muscle and/or to improve the muscle fiber size and/or to improve the level of at least one amino acid are disclosed. Also disclosed are methods and compositions comprising urolithin to improve the level of at least one metabolic product and/or to improve the level of at least one nucleotide and/or to improve the level of at least one nicotinamide adenine dinucleotide and/or to increase the level of glutathione (GSH) and/or glutathione disulfide (GSSG) and/or to increase the level of succinate and/or malate and/or to increase the level of phosphocreatine.